Artiva Biotherapeutics, Inc.ARTVEarnings & Financial Report
Nasdaq
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing off-the-shelf natural killer (NK) cell therapies for the treatment of cancers and autoimmune diseases. Its product pipeline covers both hematologic malignancies and solid tumors, and it operates primarily in the global biopharmaceutical sector, advancing accessible, high-efficacy immunotherapies to address unmet patient medical needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | 40.60% | 9.9M | ▼ -1.70pp | 2024-09-03 |
| GC Corp. | 19.60% | 4.6M | — | 2024-07-29 |
| Venrock Healthcare Capital Partners III, L.P. | 6.90% | 1.6M | — | 2024-08-01 |
| venBio Global Strategic Fund III, L.P. | 6.30% | 1.5M | ▼ -1.50pp | 2024-11-14 |
| Andrew J. Schwab | 5.00% | 1.2M | — | 2024-08-01 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-10 | Huston Thad Allen | Chief Financial Officer | Grant | 220.0K | $0.00 | $0 |
| 2026-02-15 | Subhashis Banerjee | Chief Medical Officer | Grant | 102.0K | $0.00 | $0 |
| 2026-02-15 | Jennifer Bush | COO, CLO, Secy, Compliance Off | Grant | 117.3K | $0.00 | $0 |
| 2026-02-15 | Heather Raymon | SVP, Research and Development | Grant | 46.0K | $0.00 | $0 |
| 2026-02-15 | Christopher Horan | Chief Tech Operations Officer | Grant | 117.3K | $0.00 | $0 |
| 2026-02-15 | Fred Aslan | President and CEO | Grant | 366.9K | $0.00 | $0 |
1–6 of 6